NewsRelease

JournalArticle Cites HemoVoid™ in Biomarker Quantification for LC-MSProteomic Analysis of Erythrocytes in Parkinson’s Disease

MONMOUTHJUNCTION, NJ, February13,2020 -- Biotech Support Group reports on a recent research articledescribing the simplicity and efficiency of their hemoglobindepletion technology for enriching the red cell low abundanceproteome, to quantify abundance changes in red cells that might occurin Parkinson’s Disease.

Thecitation is:

Klatt,Stephan, et al. "Optimizingred blood cell protein extraction for biomarker quantitation withmass spectrometry." Analyticaland Bioanalytical Chemistry (2020):1-14.

Redblood cells (RBCs) might serve as a reservoir for biomarker researchas they are anuclear and lack the ability to synthesize proteins. Yetfew biomarker assays have been conducted on RBCs because of theirlarge dynamic range of proteins, high abundance of lipids, and thelarge amount of hemoglobin interference. In this study, the author’sdeveloped a semiquantitative mass spectrometry–based assay thattargeted 144 proteins and compared the efficiency of urea, sodiumdeoxycholate, acetonitrile, and HemoVoid™ as a sample prep step forthe RBC proteome. The article describes the advantage of HemoVoid™in detection of low abundance proteins when comparing their amounts(in percent) between with the other four extraction conditions. Withrespect to Parkinson’s Disease, the article states “For example,PRDX6 accounts for 0.4% of the total ion abundance after DOC(deoxycholate) extraction, whereas following HV (HemoVoid™)extraction, this increases to 8%, a 20-fold enrichment”. Theauthors conclude that the HemoVoid™ method significantly reducesthe concentration of hemoglobin, resulting in an increased signal-tonoise of the remaining proteins. This is especially useful for lowabundance proteins and for those which might be close to the limit ofdetection without depletion. 

“Hereis another HemoVoid™ report demonstrating a very importantadvantage, that through a negative selection strategy, you candeplete Hemoglobin as it very selectively passes through the beadswithout binding. By that process, you can achieve enrichment of theunderlying red cell proteome which can then be on-bead digested,greatly simplifying the workflow. This we hope will lead to newbiomarkers for many diseases like Parkinson’s”, states SwapanRoy, Ph.D., President and Founder of Biotech Support Group. 

Formore information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

Formore information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Articles.asp?ID=452

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com

Contact:
MatthewKuruc 732-274-2866, [email protected]